The new era of hepatitis C virus therapy

The hepatitis C virus (HCV) has a significant medical and economic impact on societies around the world, and it has been estimated that 130-180 million people are infected with HCV. Therapies for HCV are currently undergoing a revolution. In recent years, several new treatments have been approved by...

Full description

Saved in:
Bibliographic Details
Published in:Saudi journal of gastroenterology 2015-11, Vol.21 (6), p.345-354, Article 345
Main Author: Al-Judaibi, Bandar
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral Agents - economics
Antiviral Agents - therapeutic use
Care and treatment
Cirrhosis and null responders
Complications and side effects
direct antiviral agents
Drug Therapy, Combination
Genotype
Health aspects
Hepacivirus - isolation & purification
Hepatitis C
Hepatitis C virus
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - economics
Hepatitis C, Chronic - epidemiology
Humans
Nucleic Acid Synthesis Inhibitors - therapeutic use
Prevalence
Review
Serine Proteinase Inhibitors - therapeutic use
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The hepatitis C virus (HCV) has a significant medical and economic impact on societies around the world, and it has been estimated that 130-180 million people are infected with HCV. Therapies for HCV are currently undergoing a revolution. In recent years, several new treatments have been approved by the United States Food and Drug Administration, and many other treatments are in phase II or III clinical trials, including direct antiviral agents (DAAs). Due to recent major advances in the field of HCV therapy, a summary of findings on new HCV therapies are provided in this review article, including reports on new DAAs.
ISSN:1319-3767
1998-4049
DOI:10.4103/1319-3767.170947